Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Schultz, Nicolai A ^a,d,i   Christensen, Ib J ^b   Werner, Jens ^c   Giese, Nathalia ^c   Jensen, Benny V ^d   Larsen, Ole ^d   Bjerregaard, Jon K ^e   Pfeiffer, Per ^e   Calatayud, Dan ^a   Nielsen, Svend E ^f   Yilmaz, Mette K ^g   Holländer, Niels H ^h   Wøjdemann, Morten ⁱ   Bojesen, Stig E ⁱ   Nielsen, Kaspar R ^g   Johansen, Julia S ^d,i  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d Mental Health Center Glostrup   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f HILLERØD HOSPITAL   (Denmark)

^g AALBORG UNIVERSITY HOSPITAL   (Denmark)

^h NAESTVED HOSPITAL   (Denmark)

ⁱ GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CAPECITABINE; CHITINASE 3 LIKE 1; ERLOTINIB; FLUOROURACIL; GEMCITABINE; GLYCOPROTEIN; INTERLEUKIN 6; IRINOTECAN; OXALIPLATIN; UNCLASSIFIED DRUG; CHITINASE 3 LIKE PROTEIN 1; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; DENMARK; DIAGNOSTIC VALUE; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GERMANY; HUMAN; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PREDICTION; PREOPERATIVE EVALUATION; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SEX DIFFERENCE; BLOOD; MIDDLE AGED; PANCREATIC NEOPLASMS; PANCREATITIS; PROGNOSIS; RISK; SURVIVAL ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CA-19-9 ANTIGEN; CHITINASE-3-LIKE PROTEIN 1; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PANCREATITIS; PROGNOSIS; RISK; SURVIVAL ANALYSIS;

EID: 84879486919     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067059     Document Type: Article

References (49)

1. Siegel R, Naishadham D, Jemal A, (2012) Cancer Statistics, 2012. CA Cancer J Clin 62: 10-29.
2. Hidalgo M, (2010) Pancreatic Cancer. Review. N Engl J Med 362: 1605-1617.
3. Seufferlein T, Bachet JB, Van Custem E, Rougier P on behalf of the ESMO Guidelines Working Group. Pancreatic adenocarcinoma: (2012) ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 23 (Supplement 7): vii 33-40.
4. Ballehaninna UK, Chamberlain RS, (2012) The clinical utility of CA 19-9 in diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol 3: 105-119.
5. Johansen JS, Schultz NA, Jensen BV, (2009) Plasma YKL-40: a potential new cancer biomarker? Future Oncol 5: 1065-1083.
6. Guo Y, Xu F, Lu T, Duan Z, Zhang Z, (2012) Interleukin-6 pathway in targeted therapy for cancer. Cancer Treat Rev 38: 904-910.
7. Rehli M, Krause SW, Andreesen R, (1997) Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 43: 221-225.
8. Johansen JS, Høyer PE, Larsen LA, Price PA, Møllgård K, (2007) YKL-40 protein expression in the early developing human musculoskeletal system. J Histochem Cytochem 55: 1213-1228.
9. Brøchner CB, Johansen JS, Larsen LA, Bak M, Mikkelsen HB, et al. (2012) YKL-40 is differentially expressed in human embryonic stem cells and in cell progeny of the three germ layers. J Histochem Cytochem 60; 188-204.
10. Nielsen AR, Plomgaard P, Krabbe KS, Johansen JS, Pedersen BK, (2011) IL-6, but not TNFalfa, increases plasma YKL-40 in human subjects. Cytokine 55: 152-155.
11. Junker N, Johansen JS, Hansen LT, Lund EL, Kristjansen PEG, (2005) Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Science 96: 183-190.
12. Francescone RA, Scully S, Faibish M, Taylor SL, Oh D, et al. (2011) Role of YKL-40 in the angiogenesis, radioresistance, and progression of glioblastoma. J Biol Chem 286: 15332-15343.
13. Faibish M, Francescone R, Bentley B, Yan W, Shao R, (2011) A YKL-40 neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers. Mol Cancer Ther 10: 742-751.
14. Lee CG, Da Silva C, Dela Cruz CS, Ahangari F, Ma B, et al. (2011) Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodelling, and injury. Annu Rev Physiol 73: 479-501.
15. Eurich K, Segawa M, Toei-Shimizu S, Mizoguchi E, (2009) Potential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cells. World J Gastroenterol 15: 5249-5259.
16. Dela Cruz CS, Liu W, HE CH, Jacoby A, Gornitzky A, et al. (2012) Chitinase 3-like-1 promotes Streptoccus Pneumoniae killing and augments host tolerance to lung antibacterial responses. Cell Host Microbe 12: 34-46.
17. Saidi A, Javerzat S, Bellahcene A, De Vos J, Bello L, et al. (2008) Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma. Int J Cancer 122: 2187-2198.
18. Shao R, Hamel K, Petersen L, Cao OJ, Arenas RB, Bigelow C,et al. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene 28: 4456-4468.
19. Kawada M, Seno H, Kanada K, Nakanishi Y, Akitake R, Komekado H,et al. Chitinase 3-like-1 promotes macrophage recruitment and angiogenesis in colorectal cancer. Oncogene 31: 3111-23.
20. Chen C-C, Llado V, Eurich K, Tran HT, Mizoguchi E, (2011) Carbohydrate-binding motif in chitinase 3-like 1 (CHI3L1/YKL-40) specifically activates Akt signaling pathway in colonic epithelial cells. Clin Immunol 140: 268-275.
21. Lee CG, Hartl D, Lee GR, Koller B, Matsuura H, et al. (2009) Role of breast regression protein 39 (BRP-39)/Chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J Exp Med 206: 1149-1166.
22. Chang ST, Zahn JM, Horecka J, Kunz PL, Ford JM, et al. (2009) Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis. J Translational Med 7: 105.
23. Johansen JS, Bojesen SE, Mylin AK, Frikke-Schmidt R, Price PA, et al. (2009) Elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and decreased survival after any cancer diagnosis in the general population. J Clin Oncol 27: 572-578.
24. Wigmore SJ, Fearon KCH, Sangster K, Maingay JP, Garden OJ, et al. (2002) Cytokine regulation of constitutive production of interleukin-8 and-6 by human pancreatic cancer cell lines and serum cytokine concentrations in patients with pancreatic cancer. Int J Oncol. 4: 881-886.
25. Trikha M, Corringham R, Klein B, Rossi JF, (2003) Targeted anti-interleukin-6 monoklonal antibody therapy for cancer: A review of the rationale and clinical evidence. Clin Cancer Res 9: 4653-4665.
26. Martignoni ME, Kunze P, Hildebrandt W, Künzli B, Berberat P, et al. (2005) Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexia. Clin Cancer Res 16: 5802-5808.
27. Miyamoto Y, Hosotani R, Doi R, Wada M, Ida J, et al. (2001) Interleukin-6 inhibits radiation induced apoptosis in pancreas cancer cell. Anticancer Res 21: 2449-2456.
28. Barber MD, Fearon KC, Ross JA, (1999) Relationship of interleukin-6, soluble interleukin-6 receptor and tumor necrosis factor receptor to the acute-phase response in advanced pancreatic cancer. Clin Science 96: 83-87.
29. Ebrahimi B, Tucker SL, Li D, Abbruzzese JL, Kurzrock R, (2004) Cytokines in pancreatic carcinoma. Correlation with phenotypic characteristics and prognosis. Cancer 101: 2727-2736.
30. Schultz NA, Johnsson A, Johansen JS, Christensen IJ, Gunnlaugsson A, et al. (2013) Increases in plasma YKL-40 and IL-6 during chemotherapy of patients with pancreatic cancer and other upper gastrointestinal adenocarcinomas are associated with short survival. Manuscript submitted.
31. Bojesen SE, Johansen JS, Nordestgaard BG, (2011) Plasma YKL-40 levels in healthy subjects from the general population. Clin Chim Acta 412: 709-712.
32. Knudsen LS, Christensen IJ, Lottenburger T, Svendsen MN, Nielsen HJ, et al. (2008) Pre-analytical and biological variability in circulating IL-6 in healthy subjects and patients with rheumatoid arthritis. Biomarkers 13: 59-78.
33. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2006) Reporting recommendations for tumor marker prognostic studies (Remark). Breast Cancer Res Treatment 100: 229-235.
34. Schultz NA, Johansen JS, (2010) YKL-40-A protein in the field of translational medicine: A role as biomarker in cancer patients. Cancers 2: 1453-1491.
35. Høgdall EVS, Ringholt M, Høgdall CK, Christensen IJ, Johansen JS, et al. (2009) YKL-40 tissue expression and plasma levels in patients with ovarian cancer. BMC Cancer 9: 8.
36. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: The next generation. Cell 144: 646-674.
37. Pietra K, Östman A, (2010) Hallmarks of cancer: Interactions with the tumor stroma. Exp Cell Res 316: 1324-1331.
38. Hanahan D, Coussens LM (2012) Accessories to the crime: Functions of cells recruited to the tumor microenvironment. Cancer Cell 21; 309-322.
39. De Visser KE, Eichten A, Coussen LM, (2006) Paradoxial role of the immune system during cancer development. Nat Rev Cancer 6: 24-37.
40. Hamilton SR, Aaltonen LR (2000) World health organisation classification of tumors. Pathology and genetics of tumors of the gastrointestinal tract. IARC Press: Lyon 2000; 219-250.
41. Ringsholt M, Høgdall EV, Johansen JS, Price PA, Cristensen LH, (2007) YKL-40 protein expression in normal adult human tissue- an immunohistochemichal study. J Mol Histol. 38: 33-43.
42. Recklies AD, White C, Ling H, (2002) The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem J 365: 119-126.
43. Ernst M, Putoczki TL, (2012) Stat3: linking inflammation to (gastrointestinal) tumourigenesis. Clin Exp Pharmacol Physiol 39: 711-718.
44. Yang JD, Kim E, Pedersen RA, Kim WR, Pungapong S, et al. (2010) Utility of serum YKL-40 as a tumor-specific marker of hepato-biliary malignancies. Gut Liver 4: 537-542.
45. Algül H, Treiber M, Lesina M, Schmid RM, (2007) Mechanisms of disease: Chronic inflamation and cancer in the pancreas- a potential role for pancreatic stellate cells. Nat Clin Pract Gastroenterol Hepatol 8: 454-462.
46. Fujita J, Tsunjinaka T, Yano M, Ebisui C, Saito H, et al. (1996) Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-Ubiquitin-dependent proteolytic pathways. Int J Cancer 68: 637-643.
47. Tsujinaka T, Fujita J, Ebisui C, Yano M, Kominami E, et al. (1996) Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J Clin Invest 97: 244-249.
48. Wu C, Miao X, Huang L, Che X, Jiang G, et al. (2012) Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations. Nature Genetics 44: 62-66.
49. He M, Wu C, Xu J, Guo H, Yang H, et al. (2013) A genome wide association study of genetic loci that influence tumour biomarkers cancer antigen 19-9, carcinoembryonic antigen and α fetoprotein and their associations with cancer risk. Gut. Epub ahead of print. doi:10.1136.